-
-
-
-
-
-
-
Acer Therapeutics (ACER) Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
-
-
-
-
-
-
-
Acer Therapeutics (ACER) Announces Data Presentation
-
-
-
-
-
-
-
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
-
-
-
-
-
-
-
Acer Therapeutics (ACER) and Relief Announce FDA Approval of OLPRUVA
-
-
-
-
-
-
-
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
-
-
-
-
-
-
-
Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

